Unraveling the gut-Lung axis: Exploring complex mechanisms in disease interplay
Mariam Wed Eladham,
Balachandar Selvakumar,
Narjes Saheb Sharif-Askari,
Fatemeh Saheb Sharif-Askari,
Saleh Mohamed Ibrahim,
Rabih Halwani
Affiliations
Mariam Wed Eladham
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
Balachandar Selvakumar
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
Narjes Saheb Sharif-Askari
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
Fatemeh Saheb Sharif-Askari
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; Department of Pharmacy Practice and Pharmaceutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates
Saleh Mohamed Ibrahim
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
Rabih Halwani
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Prince Abdullah Ben Khaled Celiac Disease Research Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Saudi Arabia; Corresponding author. College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
The link between gut and lung starts as early as during organogenesis. Even though they are anatomically distinct, essential bidirectional crosstalk via complex mechanisms supports GLA. Emerging studies have demonstrated the association of gut and lung diseases via multifaceted mechanisms. Advancements in omics and metagenomics technologies revealed a potential link between gut and lung microbiota, adding further complexity to GLA. Despite substantial studies on GLA in various disease models, mechanisms beyond microbial dysbiosis regulating the interplay between gut and lung tissues during disease conditions are not thoroughly reviewed. This review outlines disease specific GLA mechanisms, emphasizing research gaps with a focus on gut-to-lung direction based on current GLA literature. Moreover, the review discusses potential gut microbiota and their products like metabolites, immune modulators, and non-bacterial contributions as a basis for developing treatment strategies for lung diseases. Advanced experimental methods, modern diagnostic tools, and technological advancements are also highlighted as crucial areas for improvement in developing novel therapeutic approaches for GLA-related diseases. In conclusion, this review underscores the importance of exploring additional mechanisms within the GLA to gain a deeper understanding that could aid in preventing and treating a wide spectrum of lung diseases.